Form D · Biotechnology

Merus N.V.

3584 Cm Utrecht, P7 · CIK 0001651311

Offering snapshot reported Jan 2, 2019 · SEC filing

Reported sold
$15M
Offering amount: $15M
Investors reported
1
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 20, 2018
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jan 2, 2019Initial$15,000,000No comparison1SEC filing
Feb 28, 2018Initial$55,799,946No comparison9SEC filing
Jan 24, 2017Initial$80,000,000No comparison1SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-329437

Source: Form D, filed Jan 2, 2019. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Lex Bakker Executive
Wolfgang Berthold Director
Lionel M.S. Carnot Director
John Crowley Executive
John P. De Koning Director
John De Kruif Executive
Russell Greig Director
Mark T. Iwicki Director
Len Kanavy Director
Hui Liu Executive
Ton Logtenberg Director, Executive
Shelley Margetson Executive
Anand Mehra Director
Jack B. Nielsen Director
Gregory D. Perry Director
Peter Silverman Executive
L. Andres Sirulnik Executive
Mark Throsby Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
Yalelaan 62
3584 Cm Utrecht, P7, 3584 CM